Sherwin-Williams and Valspar Merger Delayed
Completion of the merger of US paint companies Sherwin-Williams and Valspar has been postponed from Mar. 21 to Jun. 21, 2107 because of delays related to the sale of one of Sherwin-William’s businesses that is required before regulators can clear the deal.
Sherwin-Williams has not identified the business it is trying to sell. However, the Cleveland, Ohio-based group confirmed that the required divestment will not impact the price of $113 per share that it has agreed to pay. Under the original agreement, if regulators required Sherwin-Williams to sell assets totaling more than $650 million in annual revenues, the purchase price for Valspar would fall to $105 per share.
John Morikis, chairman, president and CEO of Sherwin-Williams, said the company is in discussions with a number of prospective buyers and it continues to move forward on the divestment of a single business that it believes would allow the Federal Trade Commission to grant approval. He commented: “We remain confident in our ability to complete the divestiture at a fair price and we look forward to unlocking the value of the combined business when the Valspar acquisition closes”.
Sherwin-Williams said the extension to June should provide enough time to complete both transactions. It expects to provide more definitive timing during its first-quarter earnings conference call scheduled for Apr. 20.
The Valspar deal is reported to be the largest acquisition in Sherwin-William’s 150-year history.
most read
Orion Announced Plans to Shut Down Carbon Black Plants
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.
MSD to Acquire Verona Pharma for $10 Billion
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
Roche and Zealand Pharma Collaborate on Weight Management Drug
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
Oxea Appoints Michael McHenry as New Chief Executive Officer
German oxo-chemicals manufacturer Oxea has appointed Michael McHenry as its new CEO with effect from August 15, 2025.
Boehringer Ingelheim Paves the Way for Important Market Launches
Boehringer Ingelheim recorded positive growth in the first half of 2025 with an increase in Group sales of 6.3% to € 14 billion.